Sagimet Biosciences Inc. - SGMT Total Company Value-to-Revenue Ratio

sagimet.com (SGMT) - corporate logo

The EV-to-revenue multiple demonstrates the market's perception of the business value, while 0.00 reflects the baseline level of the metric. Sagimet Biosciences (SGMT) focuses on developing targeted therapies for liver diseases via FASN inhibitors. Prospects depend on the approval of drugs against NASH and patent protection. Potential pricing power in the MASH niche will ensure premium status following FDA certification.

SGMT Sagimet Biosciences: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 11/20/2026

Sagimet Biosciences, Inc. - analytical breakdowns and key metrics (SGMT)

- cash and cash flow indicators:
Fundamental company valuation:SGMT Sagimet Biosciences
Original product of Sagimet Biosciences Inc.

The EV/Sales ratio measures business value relative to revenue, excluding the impact of debt load. Professionals use it to assess the market premium paid per unit of sales. The current value of 0.00 on the EV/Sales chart from GURU.Markets reflects the current balance of supply and demand. A stabilization of the trend may signal a risk of capital stagnation. For Sagimet Biosciences (SGMT), this confirms the effectiveness of biocomponent supplier diversification, which supports profitability.

Competitor analysis for Sagimet Biosciences

ASND: Enterprise Value-to-Revenue Ratio|MDGL: EV/Sales Multiple|CORT - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Rhythm Corp|Akero Corp (AKRO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio metsera.com (MTSR)|Company Value to Revenue moonlaketx.com MLTX|EV/Sales Multiple CRNX (Crinetics Pharmaceuticals, Inc.)|NAMS: Company Value to Revenue Ratio|SLNO - Enterprise Value-to-Revenue Ratio|Amicus Pharma (FOLD) - Company Value to Revenue|ETNB: EV/Sales Multiple|AGIO - Total Company Value-to-Revenue Ratio|Company Value to Revenue GPCR|Enterprise Value-to-Revenue Multiple MiMedx MDXG|Enterprise Value-to-Revenue Ratio Rezolute Corp (RZLT)|Company Value to Revenue Lexicon Corp LXRX|Enterprise Value-to-Revenue Ratio MBX Biosciences, Inc. MBX|EV/Sales Multiple altimmune.com ALT|AARD - Enterprise Value-to-Revenue Ratio|Business Value to Revenue BIOA (BioAge Labs)|BMEA: EV/Sales Multiple|QNCX: Enterprise Value-to-Revenue Coefficient|GUTS (Fractyl Health, Inc.) - EV/Sales Multiple|EV/Sales Multiple vtvtherapeutics.com|Company Value to Revenue ATPC (Agape ATP Corp)|Total Company Value-to-Revenue Ratio Pluristem Therapeutics|Enterprise Value-to-Revenue Ratio synlogictx.com SYBX|LPCN: Company Value to Revenue Ratio|MTNB - Enterprise Value-to-Revenue Ratio|Spruce Biosciences, Inc. (SPRB) - Company Value to Revenue|GLTO: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Carmell Corp. (CTCX)|LUMO (Lumos Therapeutics) - EV/Sales Multiple|Organovo Corp (ONVO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Radius Recycling (RDUS)